Neogen's Turnaround Accelerates: Food Safety Core Growth Hits Highest Since 3M Deal, R&D Spend to Jump 50%

The commercial engine is turning

Neogen's fiscal Q4 results delivered the clearest signal yet that the operational turnaround is gaining real traction. Food Safety core growth reached 5.8% — the highest level since the period immediately following the 3M acquisition — while Animal Safety returned to positive core growth after a year of supply-driven declines. The market noticed: the stock is up roughly 27% over the last 90 trading days, a sharp reversal from the deep drawdown that dragged it from its 2021 peak.

The tone on the call was unapologetically offensive. New Chief Commercial Officer Joe Freels described a “meaningful cultural transformation” — Joe Freels, Chief Commercial Officer · 2026-07-30 across the commercial organization, with a focus on share gain rather than just holding ground. The company is now prioritizing a focused set of 14 countries, building a dedicated strategic account function, and shifting from product-centric selling to solutions-based engagement. That shift is already showing up in the numbers — gross margin improved 330 bps year-over-year in Q4, even with freight and material cost pressure.

Petrifilm and the R&D step-up

The most consequential driver is the manufacturing transition for Petrifilm. Management confirmed the first fully validated SKU should be complete in August, with the multi-quarter production transition to begin in November. This is a major derisking event — as CEO Mikhael Nassif put it, “a major derisking event for this entire program.” — Mikhael Nassif, Chief Executive Officer · 2026-07-30 The company also plans to increase R&D investment by ~50% in fiscal 2027, approaching 5% of revenue over time. That is a deliberate departure from the prior decade’s flat R&D spend. R&D expense has hovered in the $4–7M range for ten years, with no real growth since 2023. The new investment is aimed at building a pipeline of next-gen platforms and supporting 2 new Petrifilm SKUs per year.

The prior-quarter calls hinted at this pivot. Back in January, Mike Nassif noted the need to “drive the specificity and commercial excellence” — Mike Nassif, Chief Executive Officer · 2026-01-08 and hinted at reinvesting for growth. Now the commitment is explicit: “We can't wait until we feel ready to do innovation,” Nassif said on this call, “because the innovation cycle on some of these products is 18 to 24 months.” — Mikhael Nassif, Chief Executive Officer · 2026-07-30 That urgency is why the company is willing to accept only modest EBITDA expansion in FY27 — the investments are intentionally front-loaded.

Guidance and the path to 30% margins

The FY27 guidance of $880–$885M revenue and $180–$182M adjusted EBITDA implies roughly 3% core growth and 20.5% adjusted EBITDA margin. CFO Bryan Riggsbee was clear about the trade-off:

We're bringing forward some of these investments before we actually see the benefit from some of the operating efficiencies… over time, we think we have the opportunity to get to 30%.

Management is also betting on the macro tailwinds: food safety recalls are at an 8-year high, China is implementing FSMA-like regulations, and litigation pressures are rising. The company sees volume growth turning positive in food production after being flat. Commercial organization is being restructured to capture that. And on the balance sheet, the pending genomics divestiture for $140M will further reduce net leverage — which ended the quarter at roughly $794M gross debt and $185.5M cash.

In the prior quarter, CFO Bryan Riggsbee had already flagged the plan to pay down debt and reinvest. Now the sequencing is clear: use the divestiture proceeds to strengthen the balance sheet while funding the operational leap. The tape is voting yes — the recent 90-day return of +26.9% reflects growing investor confidence that this is not just a beat-and-raise quarter but a genuine inflection.